Abstract Library

#3303 Lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumors - An international double-blind, placebo-controlled randomized phase 2. Prodige 31 REMINET. A FFCD study

Introduction: Following European guidelines, patients (pts) with aggressive metastatic or locally advanced, non-resectable, duodeno-pancreatic (DP) neuroendocrine tumors (NETs), should receive systemic combination of chemotherapy until progression. Aggressive disease is defined as progressive and/or symptomatic metastases and/or with significant hepatic invasion (>30-50%), and/or bone metastases.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Lepage C

Authors: Lepage C, Phelip J, Lievre A, Le Malicot K, Dahan L,

Keywords: clinical trial, non-resectable, duodeno-pancreatic, neuroendocrine tumor, maintenance,

#1763 REMINET: A European, Multicenter, Phase II/III Randomized Double-Blind, Placebo-Controlled Study Evaluating Lanreotide As Maintenance Therapy after First-Line Treatment in Patients with Non-Resectable Duodeno-Pancreatic Neuroendocrine Tumors

Introduction: Patients (pts) with metastatic or locally advanced, non-resectable, grade 1 or 2 Well-differentiated duodeno-pancreatic (WDDP) NETs are treated following European guidelines. Pts with aggressive disease, i.e. progressive and/or symptomatic metastases and/or with significant hepatic invasion (> 30-50%), and/or bone metastases, anti-tumour therapy should receive systemic combination of chemotherapy once disease control is obtained.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Lepage C

Authors: Lepage C, Dahan L, Legoux J, Le Malicot K, Guimbaud R,

Keywords: Duodeno-pancreatic neuroendocrine tumours, clinical trial, maintenance,